What They Are
SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) are antidepressant medications that also reduce vasomotor symptoms through their effects on the thermoregulatory center. They are the most commonly prescribed non-hormonal treatment for hot flashes.
Paroxetine at 7.5 mg (brand name Brisdelle) is the only SSRI FDA-approved specifically for menopausal vasomotor symptoms. This dose is lower than antidepressant doses (20-40 mg) and has a different side effect profile. Several other SSRIs and SNRIs are used off-label for this purpose.
The Options
Paroxetine 7.5 mg (Brisdelle/generic). FDA-approved for vasomotor symptoms. Reduces hot flash frequency by approximately 40 to 65%. Onset within 1 to 2 weeks (faster than antidepressant-dose onset). Side effects at this dose are generally mild. CRITICAL: do NOT use with tamoxifen - paroxetine inhibits CYP2D6 and reduces tamoxifen effectiveness. Generic available at $4 to 15 per month.
Venlafaxine 37.5-150 mg. SNRI. Probably the most studied off-label option after paroxetine. Reduces hot flashes by approximately 40-60%. Also effective for mood symptoms. May increase blood pressure at higher doses - monitor. Generic $4 to 20 per month.
Desvenlafaxine 100-150 mg. Active metabolite of venlafaxine. Similar efficacy. May have fewer drug interactions than venlafaxine. Generic $10 to 40 per month.
Escitalopram 10-20 mg. SSRI. Evidence for hot flash reduction (approximately 40-50%). Well-tolerated. Good option when mood and vasomotor symptoms coexist. Generic $4 to 15 per month.
Citalopram 10-20 mg. Similar to escitalopram. Some evidence for vasomotor symptoms. QTc prolongation risk at higher doses. Generic $4 to 15 per month.
Who They Are Best For
Women with contraindications to HRT who need vasomotor symptom relief. Women with coexisting depression or anxiety where a single medication addresses both. Women who prefer non-hormonal treatment. Women on tamoxifen (use venlafaxine or desvenlafaxine - avoid paroxetine and fluoxetine due to CYP2D6 interaction). Women whose vasomotor symptoms are not fully controlled by HRT and who want add-on therapy.
Efficacy vs HRT
This comparison matters for informed decision-making. HRT reduces hot flash frequency by 75 to 95%. SSRIs/SNRIs reduce frequency by 40 to 65%. The gap is real. For women with severe vasomotor symptoms, SSRIs/SNRIs may provide meaningful improvement but not full resolution. For women with mild-to-moderate symptoms, they may be sufficient.
Side Effects
Common across the class: nausea (usually transient), headache, dizziness, sexual dysfunction (decreased libido, anorgasmia - important to discuss given that menopause already affects sexual function), insomnia or drowsiness (agent-dependent), weight changes.
SSRI/SNRI-specific: serotonin syndrome risk when combined with other serotonergic medications. Withdrawal symptoms if stopped abruptly (taper required). Hyponatremia (low sodium) risk, particularly in older adults.
The sexual side effect deserves emphasis. Women taking SSRIs/SNRIs for menopausal symptoms may experience medication-induced sexual dysfunction on top of menopause-related sexual changes. This should be discussed openly when choosing between options.
Practical Considerations
Start low, increase if needed. Many women get adequate vasomotor benefit at low doses that produce fewer side effects than antidepressant doses. Do not stop abruptly - all SSRIs/SNRIs require gradual tapering to avoid discontinuation syndrome (dizziness, nausea, irritability, “brain zaps”). Effect on hot flashes begins within 1 to 2 weeks for most agents, which is faster than the 4 to 6 week onset for antidepressant effect. If vasomotor symptoms are the primary indication, evaluate response at 4 to 6 weeks. If no meaningful improvement, consider switching agents or adding another approach.
Questions To Ask A Clinician
- Which SSRI/SNRI is best for my situation given my other medications and symptoms?
- Am I taking tamoxifen? (If yes, avoid paroxetine and fluoxetine)
- What dose should I start at, and how quickly can we titrate?
- How does the expected benefit compare to what HRT would provide?
- What is the plan if this does not provide adequate relief?
- How do I safely taper off if I want to stop?